Omaxe Ltd

Omaxe Ltd.'s financial performance reveals significant challenges. The company has experienced a decline in profitability, coupled with inconsistent sales growth. The negative operating profit margins and net profit margins underscore operational inefficiencies and difficulties in converting revenue into profit.

Omaxe Ltd. has exhibited substantial variability in its YOY Sales Growth %. This is highlighted by figures such as 0.45% in Mar 2022, 145.72% in Dec 2023, and a sharp decline to -51.78% in Dec 2024. The negative operating profit, which was -109 in Mar 2023, further deteriorated to -146 in Mar 2024 and remained significantly negative at -106 in Mar 2025. These financial metrics indicate a struggle in maintaining consistent and sustainable financial performance, reflecting potential operational inefficiencies and market challenges.

Omaxe Ltd. demonstrates poor capital efficiency and returns. The negative ROCE and ROE values indicate that the company is not effectively utilizing its capital to generate profits, which raises concerns about its financial sustainability and attractiveness to investors.

The Return on Capital Employed (ROCE) has declined significantly. The ROCE % decreased from 8% in Mar 2014 to -61% in Mar 2025, signaling a diminishing efficiency in capital utilization. Similarly, the Return on Equity (ROE) has also deteriorated, with a current ROE of -14.87, highlighting the company's inability to generate returns on shareholder equity. These metrics suggest that Omaxe Ltd. faces substantial challenges in leveraging its capital effectively to produce profits, raising concerns about its overall financial health and investment viability.

Omaxe Ltd.'s financial health is weak due to its debt levels.

The Borrowings show Omaxe Ltd. has maintained a significant level of debt over the years. The Borrowings which was 1299 in Mar 2014 has decreased to 796 in Mar 2025. The interest has increased from 131 in Mar 2014 to 195 in Mar 2025.

Omaxe Ltd. faces challenges in its strategic and operational indicators. The increasing cash conversion cycle indicates inefficiencies in working capital management, which can tie up resources and negatively impact liquidity.

The Cash Conversion Cycle has increased significantly, with a Cash Conversion Cycle of 197 days in Mar 2014 to 1,827 days in Mar 2025, indicating longer periods to convert investments into cash. The inventory days also increased from 16,214 in Mar 2024 to 1,996 in Mar 2025.

There is no specific data available on off-balance sheet exposure quantification.

There is no specific data available on contingent liability evaluation.

There is no specific data available on accounting quality red flags.

There is no specific data available on segment performance volatility.

There is no specific data available on foreign exchange or interest rate exposure.

There is no specific data available on regulatory compliance cost trends.